Cargando…

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma

Multitargeted receptor tyrosine kinase inhibitors, including vascular endothelial growth factor (VEGF) inhibitors, such as sunitinib, have been used as the primary targeted agents for patients with recurrent or distant metastasis of advanced renal cell carcinoma (RCC). However, endogenous or acquire...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukumoto, Wataru, Yoshino, Hirofumi, Horike, Shin‐Ichi, Kawakami, Issei, Tamai, Motoki, Arima, Junya, Kawahara, Ichiro, Mitsuke, Akihiko, Sakaguchi, Takashi, Inoguchi, Satoru, Meguro‐Horike, Makiko, Tatarano, Shuichi, Enokida, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551594/ https://www.ncbi.nlm.nih.gov/pubmed/37545017 http://dx.doi.org/10.1111/cas.15914

Ejemplares similares

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients
por: Tatarano, Shuichi, et al.
Publicado: (2022)

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
por: Tamai, Motoki, et al.
Publicado: (2022)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report
por: Yamada, Yasutoshi, et al.
Publicado: (2019)

Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
por: Mitsuke, Akihiko, et al.
Publicado: (2023)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

Topical estrogen application promotes cutaneous wound healing in db/db female mice with type 2 diabetes
por: Mukai, Kanae, et al.
Publicado: (2022)

First report of inherited protein S deficiency caused by paternal PROS1 mosaicism
por: Nagaya, Satomi, et al.
Publicado: (2021)

Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons
por: Lopez, S. Jesse, et al.
Publicado: (2017)

Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II
por: Takeda, Yoshimichi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Regulatory Peptides from Chromogranin A and Secretogranin II
por: Helle, Karen B.
Publicado: (2010)

Functional Investigation of a Non-coding Variant Associated with Adolescent Idiopathic Scoliosis in Zebrafish: Elevated Expression of the Ladybird Homeobox Gene Causes Body Axis Deformation
por: Guo, Long, et al.
Publicado: (2016)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice
por: Taketani, Hiroyoshi, et al.
Publicado: (2019)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011)

An antibody against secretogranin I (chromogranin B) is packaged into secretory granules
Publicado: (1989)

Conditional knockout of the secretogranin II gene to reveal biological functions of secretoneurin
por: Leierer, Johannes, et al.
Publicado: (2008)

Secretogranin II influences the assembly and function of MHC class I in melanoma
por: Steinfass, Tamara, et al.
Publicado: (2023)

Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer
por: CHIYOMARU, TAKESHI, et al.
Publicado: (2014)

TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3
por: Schecterson, Leslayann C., et al.
Publicado: (2020)

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer
por: Matsushita, R, et al.
Publicado: (2015)

Mysterious inhibitory cell regulator investigated and found likely to be secretogranin II related
por: Hart, John E., et al.
Publicado: (2017)

Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy
por: LeBlanc, Michelle E., et al.
Publicado: (2017)

Epitope mapping of an uncertain endogenous antigen implies secretogranin II peptide splicing
por: Howlett, David R., et al.
Publicado: (2019)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Secretogranin II; a Protein Increased in the Myocardium and Circulation in Heart Failure with Cardioprotective Properties
por: Røsjø, Helge, et al.
Publicado: (2012)

Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy
por: Ji, Liyang, et al.
Publicado: (2023)

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2
por: Nishimura, Tatsunori, et al.
Publicado: (2018)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_if11fibl2o020svpinv7kcqf1f